In England, 12 clinical commissioning groups had been using Avastin in wet AMD, and Novartis and Bayer called for a judicial review in a bid to make them use more expensive licensed alternatives.

s recently disclosed plans to launch biosimilar Pavblu as much as a year earlier than expected. At the same time, competitor Avastin (bevacizumab, Roche AG) has had trouble lately with supply ...

It stops the growth of blood vessels that threaten your eyesight. Aflibercept (Eylea), bevacizumab (Avastin), brolucizumab (Beovu), and ranibizumab (Lucentis) are anti-VEGF drugs used to treat wet ...

Amgen and Allergan's biosimilar of Roche’s cancer drug Avastin is on the cusp of approval in Europe, but a launch could be years away because of patent protection. While the US patent on Avastin ...